The Pediatric Burden of Primary Immune Deficiencies: A Quality of Life Perspective

Mervat Abdallah Hesham[1], Nilly Raafat Abd Elfattah[2], Mohamed Abd ElKader El Malki[3], Heba Mohammed Abdel Atti[4]

1 Professor of Pediatrics, Faculty of Medicine, Zagazig University,

2 Professor of Psychiatry, Faculty of Medicine, Zagazig University,

3 Professor of Pediatrics, Faculty of Medicine, Zagazig University,

4 Resident of Neonatology at Al-Ahrar Teaching Hospital

Corresponding author: Heba Mohammed Abdel Atti

ABSTRACT

Background: Primary immune deficiency diseases (PIDDs) represent a diverse group of over 450 genetic disorders that compromise the immune system's function, leading to heightened susceptibility to infections, autoimmunity, and malignancy. In pediatric populations, these chronic conditions significantly disrupt physical health, emotional well-being, and social integration, resulting in a markedly reduced health-related quality of life (HRQoL). This review explores the multidimensional burden of PIDD on affected children and their families, emphasizing both clinical and psychosocial domains. Frequent infections and medical interventions often result in prolonged school absences, impaired academic performance, and limited social engagement. These limitations contribute to emotional distress, including anxiety, depression, and low self-esteem, which are frequently underrecognized but critically important to the child's development and quality of life. Delayed diagnosis, often due to the rarity and heterogeneity of these disorders, further exacerbates disease progression and psychological burden. Although treatments such as immunoglobulin replacement therapy (IRT) and hematopoietic stem cell transplantation (HSCT) can improve clinical outcomes, they may also introduce new challenges, including treatment fatigue and lifestyle restrictions. Family members, especially parents and siblings, are also deeply affected, experiencing stress, financial strain, and emotional burden, which in turn influence the child's social environment. Access to multidisciplinary care—including psychological counseling, peer support groups, educational accommodations, and telehealth—has been shown to mitigate some of these burdens and improve HRQoL outcomes. Additionally, school-based interventions and awareness programs are essential for promoting inclusivity and continuity in education. Emerging therapies, such as gene therapy, offer hope for long-term disease modification, but equitable access and long-term follow-up remain critical issues. Cultural stigmas and healthcare disparities further complicate the management of PIDD, particularly in underserved populations. This review underscores the need for comprehensive, patient-centered care models that integrate medical, psychological, educational, and social support to holistically address the needs of children living with PIDD. By adopting such strategies, it is possible to significantly enhance quality of life outcomes and empower children and their families to lead more fulfilling lives.

Keywords: Primary Immune Deficiencies, Quality of Life

1. INTRODUCTION

Primary immune deficiency diseases (PIDDs) are a group of over 450 rare, chronic disorders in which part of the body's immune system is missing or functions improperly. These diseases are typically inherited and present early in life, although some may not manifest until later. PIDDs result from genetic mutations affecting components of both the innate and adaptive immune systems. Children with these conditions are particularly susceptible to infections, autoimmune diseases, and certain malignancies due to their compromised immune response [1].

One of the most common manifestations of PIDDs in children is recurrent, severe, or unusual infections. These infections may affect various systems including respiratory, gastrointestinal, and integumentary systems. Common signs include chronic ear infections, pneumonia, sinusitis, and skin abscesses. The frequency and severity of infections often exceed those typically seen in healthy children, prompting further immunological investigation [2].

Diagnosis of PIDDs in children requires a thorough medical history, physical examination, and specialized laboratory testing. Initial blood tests may include complete blood counts, immunoglobulin levels, and lymphocyte subsets. More specific diagnostic evaluations such as genetic testing and functional immune assays can confirm the specific type of immunodeficiency and guide treatment [3]. Early recognition and diagnosis are crucial to prevent irreversible organ damage and improve outcomes. Delayed diagnosis can lead to complications such as bronchiectasis, failure to thrive, and chronic gastrointestinal inflammation. Pediatricians and other healthcare providers must maintain a high index of suspicion, especially in children with persistent, atypical, or severe infections [4].

Primary immune deficiencies are broadly classified into categories based on the component of the immune system affected, including antibody deficiencies, combined immunodeficiencies, phagocytic defects, complement deficiencies, and immune dysregulation disorders. Among these, antibody deficiencies, such as X-linked agammaglobulinemia (XLA) and common variable immunodeficiency (CVID), are the most frequently diagnosed in children [5].

X-linked agammaglobulinemia is a rare condition characterized by the near absence of B cells and immunoglobulins due to mutations in the BTK gene. Affected boys typically present within the first year of life with recurrent bacterial infections. Without treatment, these children are at risk for severe complications including chronic lung disease and meningitis [6].

Common variable immunodeficiency is another form of antibody deficiency that often presents in older children or adolescents. It is marked by low levels of serum immunoglobulins and poor specific antibody responses. Unlike XLA, CVID affects both genders and has a broader range of clinical presentations, including autoimmune manifestations and gastrointestinal disease [7].

Severe combined immunodeficiency (SCID) represents one of the most critical forms of PIDD. Often called "bubble boy disease," SCID is characterized by profound defects in both T and B lymphocytes. Infants with SCID typically present with failure to thrive, chronic diarrhea, and opportunistic infections. Without early intervention, SCID is uniformly fatal within the first year of life [8].

Early detection of SCID through newborn screening programs has revolutionized its management. In many developed countries, SCID screening is now a routine part of newborn testing. Early identification enables timely interventions such as hematopoietic stem cell transplantation (HSCT), which can be curative if performed early [9].

Phagocytic cell defects, such as chronic granulomatous disease (CGD), are another important subset of PIDDs in children. CGD is characterized by defective neutrophil oxidative burst activity, leading to recurrent infections with catalase-positive organisms and granuloma formation. These children often suffer from deep-tissue abscesses and severe inflammation [10].

Complement deficiencies, though less common, can also lead to severe infections, particularly with encapsulated bacteria like Neisseria meningitidis. These conditions may go unrecognized until a child develops meningitis or other invasive infections. Complement component deficiencies are typically diagnosed via functional assays such as CH50 or AH50 testing [11].

In addition to infections, children with PIDDs are at increased risk of autoimmune disorders. The impaired immune regulation seen in many PIDDs can lead to conditions such as autoimmune cytopenias, type 1 diabetes, and inflammatory bowel disease. These autoimmune features may be the first clue to an underlying immunodeficiency, especially when they occur in combination with recurrent infections [12].

Treatment strategies for children with PIDDs depend on the specific diagnosis and severity of immune dysfunction. Immunoglobulin replacement therapy is the cornerstone of treatment for antibody deficiencies. This can be administered intravenously or subcutaneously and helps reduce the frequency and severity of infections [13].

For more severe forms of PIDDs, especially combined immunodeficiencies and certain phagocytic defects, hematopoietic stem cell transplantation offers a potential cure. Advances in conditioning regimens and donor matching have significantly improved transplantation outcomes, particularly when performed early in life [14].

Gene therapy is an emerging frontier in the treatment of certain PIDDs. Trials using gene editing technologies such as CRISPR-Cas9 have shown promise in correcting genetic mutations in conditions like SCID and CGD. These therapies offer hope for long-term correction without the need for lifelong medication or transplantation [15].

Prophylactic antibiotics and antifungals may be used in children with specific PIDDs to prevent recurrent infections. Additionally, live vaccines are generally contraindicated in children with severe

immune deficiencies, making vaccination policies an important consideration in their care. Inactivated vaccines may still be given to provide some level of protection [16].

Psychosocial support is an essential aspect of care for children with PIDDs and their families. Chronic illness, frequent hospital visits, and limitations on social interaction can lead to anxiety, depression, and social isolation. Multidisciplinary teams including psychologists and social workers can help address these challenges [17].

Education and awareness campaigns targeting both healthcare providers and the public are crucial for improving the recognition of PIDDs. Many cases remain undiagnosed or misdiagnosed for years, especially in resource-limited settings. Initiatives like the Jeffrey Modell Foundation have played a pivotal role in global advocacy and support for affected families [18].

Research into the genetic and molecular basis of PIDDs continues to uncover new disease mechanisms and therapeutic targets. Next-generation sequencing has accelerated the discovery of novel mutations and expanded our understanding of immune system complexity. These advances pave the way for more precise, personalized treatments [19].

In conclusion, children with primary immune deficiency diseases face significant medical, emotional, and social challenges. Early diagnosis, individualized treatment, and comprehensive care are essential to improving their quality of life and long-term outcomes. Continued research, education, and advocacy are vital to ensuring that these vulnerable children receive the care and support they need [20].

Diagnosis of Primary Immunodeficiency Disease in Children

Primary Immunodeficiency Diseases (PIDs) are a group of over 450 genetically determined disorders that impair the development and function of the immune system. Early diagnosis is critical, particularly in children, to prevent severe infections, immune dysregulation, and long-term complications. Children with PID may initially present with frequent or unusual infections, poor growth, or autoimmune manifestations. Recognizing these early warning signs in pediatric patients remains a clinical challenge for many healthcare providers [21].

The evaluation of suspected PID begins with a detailed medical history, including the frequency, severity, and type of infections. Recurrent infections with unusual organisms or those requiring prolonged antibiotic treatment should raise suspicion. A history of chronic diarrhea, persistent thrush, or failure to thrive in infants can also be indicative. In addition, a family history of PID or unexplained infant deaths should prompt early immunological screening [22].

Physical examination plays a vital role in the initial assessment. Findings such as lymphadenopathy, hepatosplenomegaly, eczema, or absent lymphoid tissue (e.g., tonsils or lymph nodes) can suggest an underlying immune deficiency. Specific physical anomalies may also be associated with syndromic immunodeficiencies like DiGeorge syndrome or ataxia-telangiectasia. Thus, integrating clinical

features with systemic signs is essential in identifying children who may require further immunologic testing [23].

Basic laboratory testing is often the first step in diagnosing PID. A complete blood count with differential can reveal neutropenia, lymphopenia, or eosinophilia, which may suggest cellular or combined immunodeficiencies. Quantitative immunoglobulin levels (IgG, IgA, IgM, and IgE) help identify antibody deficiencies. These initial tests can guide the direction of more specialized investigations based on suspected PID subtype [24].

Advanced immunological testing includes flow cytometry to assess lymphocyte subsets (T, B, and NK cells), which is crucial in identifying severe combined immunodeficiency (SCID) and other T-cell disorders. Functional assays, such as lymphocyte proliferation to mitogens or antigen-specific responses, provide insight into T-cell functionality. These tests are particularly important in children who present with severe infections early in life [25].

Newborn screening programs for SCID, using T-cell receptor excision circles (TRECs), have been implemented in several countries. This approach has dramatically improved early diagnosis and survival in infants with SCID by enabling treatment before the onset of life-threatening infections. TREC analysis is now a standard in many neonatal screening protocols, offering a population-wide strategy for early detection of T-cell deficiencies [26].

Genetic testing has revolutionized the diagnosis of PID by allowing the identification of specific mutations responsible for the disease. Next-generation sequencing (NGS) enables the simultaneous analysis of multiple genes associated with PIDs, providing a molecular diagnosis even in phenotypically ambiguous cases. Early genetic confirmation aids in prognosis, treatment selection, and family counseling [27].

Infections caused by opportunistic organisms in children, such as Pneumocystis jirovecii or non-tuberculous mycobacteria, are important diagnostic clues for immunodeficiency. Such infections are uncommon in immunocompetent hosts and should prompt evaluation for underlying PID. Moreover, recurrent deep-seated abscesses or osteomyelitis due to Staphylococcus aureus can indicate neutrophil defects like chronic granulomatous disease [28].

Vaccination responses also provide valuable diagnostic information. Children with poor or absent antibody responses to routine vaccinations, such as tetanus or pneumococcal vaccines, may have humoral immunodeficiencies. Specific antibody testing after immunization can reveal impaired B-cell function, even in the presence of normal immunoglobulin levels [29].

Autoimmune manifestations, such as autoimmune cytopenias or endocrinopathies, can be the presenting feature of PID. Disorders such as autoimmune lymphoproliferative syndrome (ALPS) or immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome may initially

resemble primary autoimmune diseases but are actually due to defects in immune regulation. These patients require immunological and often genetic testing for a definitive diagnosis [30].

Persistent gastrointestinal symptoms in infants and children, such as chronic diarrhea, malabsorption, and intestinal inflammation, are common in several PIDs. Conditions like common variable immunodeficiency (CVID) and IPEX may present primarily with gastrointestinal involvement. Endoscopic evaluation with biopsy, in conjunction with immunologic testing, can help establish the diagnosis [31].

Skin manifestations such as eczema, recurrent skin infections, or granulomatous lesions may also point toward specific PIDs. Wiskott-Aldrich syndrome, for example, presents with eczema, thrombocytopenia, and recurrent infections. Similarly, immune dysregulation conditions may lead to granulomatous dermatitis or other cutaneous signs, highlighting the need for dermatologic awareness in PID diagnosis [32].

Certain PIDs manifest with failure to thrive or growth retardation in infancy due to chronic infection, inflammation, or nutrient malabsorption. These signs, when accompanied by recurrent infections or laboratory abnormalities, should prompt further immunologic investigation. Nutritional and metabolic assessments may also assist in distinguishing between primary and secondary causes of growth failure [33].

Radiologic studies can support the diagnosis of PID in selected cases. Chest X-rays showing absent thymic shadow in neonates may suggest SCID or DiGeorge syndrome. High-resolution CT scans may reveal bronchiectasis or interstitial lung disease in patients with CVID or combined immunodeficiencies. These findings, though non-specific, reinforce clinical suspicion and guide further testing [34].

Prenatal and perinatal factors can influence the likelihood of PID. Consanguinity increases the risk of autosomal recessive forms of PID, while a history of prenatal complications may be seen in syndromic forms. Amniocentesis and chorionic villus sampling may allow for early genetic diagnosis in families with known mutations, allowing for early intervention or planning [35].

The diagnostic approach must also consider differential diagnoses, such as secondary immunodeficiencies from malnutrition, HIV infection, or iatrogenic causes. These conditions can mimic PIDs and need to be excluded through targeted history, serologic testing, and clinical evaluation. Ensuring accurate differentiation is critical to avoid misdiagnosis and inappropriate management [36].

Multidisciplinary evaluation often becomes necessary when PID is suspected. Immunologists, infectious disease specialists, geneticists, and pediatricians must collaborate to interpret findings and guide further steps. Multidisciplinary input ensures comprehensive care and facilitates timely diagnosis, especially in complex or atypical presentations [37].

Timely diagnosis directly impacts treatment strategies. Children diagnosed early with PID may benefit from immunoglobulin replacement, prophylactic antibiotics, or hematopoietic stem cell transplantation (HSCT), depending on the specific disorder. Delay in diagnosis can result in irreversible organ damage, disability, or even death, emphasizing the need for heightened clinical vigilance [38].

Education and awareness among healthcare providers, especially in primary care and pediatrics, are essential to improve early recognition of PID. Familiarity with the "10 warning signs" promoted by the Jeffrey Modell Foundation can aid clinicians in identifying candidates for further evaluation. Continuous medical education and diagnostic algorithms have shown promise in reducing diagnostic delays [39].

Finally, the evolving landscape of immunogenetics and diagnostic technologies is enhancing our ability to detect PID in children more effectively. Whole-exome and whole-genome sequencing, biomarker discovery, and integrated bioinformatics will likely become routine in the near future. These advances promise earlier, more accurate diagnosis and the potential for personalized treatment strategies in pediatric PID care [40].

Health-related Quality of Life in Children with Primary Immune Deficiency Diseases

Primary immune deficiency diseases (PIDDs) are a heterogeneous group of over 450 rare, chronic disorders caused by genetic defects that impair the immune system. These conditions render affected individuals highly susceptible to recurrent infections, autoimmune diseases, and malignancies. In children, the burden of PIDD can be profound, significantly altering their day-to-day activities, psychosocial functioning, and overall health-related quality of life (HRQoL) [41].

Children with PIDD often experience frequent and severe infections, which not only require repeated hospitalizations and antibiotic treatments but also interrupt their education and social development. These disruptions can lead to long-term psychosocial consequences, including anxiety, depression, and reduced self-esteem. The chronic nature of these conditions places an ongoing burden on the child and their family, thereby diminishing HRQoL across multiple domains [42].

Diagnosis of PIDD in childhood is often delayed due to the rarity and variability of clinical presentation. Such delays may result in prolonged periods of untreated illness, leading to more severe disease progression and irreversible organ damage. This delay in diagnosis exacerbates emotional distress among children and their caregivers, further reducing perceived quality of life [43].

Timely diagnosis and initiation of appropriate therapies, such as immunoglobulin replacement therapy (IRT) or hematopoietic stem cell transplantation (HSCT), are crucial for improving outcomes. These treatments can reduce the frequency of infections and hospital admissions, thereby positively influencing HRQoL. However, the burden of lifelong treatment, including regular intravenous or subcutaneous infusions, can itself be a source of stress and discomfort [44].

The psychosocial impact of PIDD is not limited to the affected child but extends to the entire family. Parents often experience heightened anxiety, guilt, and financial stress associated with their child's condition. Siblings may also feel neglected or burdened by the additional responsibilities placed upon them. This family dynamic can adversely affect the child's social environment and emotional well-being [45].

Studies have shown that children with PIDD have significantly lower scores in physical, emotional, and school functioning when assessed using standardized HRQoL instruments like the Pediatric Quality of Life Inventory (PedsQL). These findings underscore the pervasive effect of PIDD on a child's life, necessitating comprehensive management strategies that go beyond clinical treatment alone [46].

School absenteeism is a major concern for children with PIDD, who may miss substantial amounts of classroom time due to illness or medical appointments. This not only hampers academic performance but also impedes social interactions and peer relationships, further isolating the child and contributing to a diminished sense of normalcy and self-worth [47].

Social isolation is a recurring issue in children with PIDD, especially those advised to avoid crowded places to minimize infection risk. This restriction can lead to limited participation in extracurricular activities, playdates, and family outings. Over time, the lack of social engagement may result in impaired social skills and emotional development [48].

Despite the physical and emotional challenges, some children with PIDD exhibit remarkable resilience and adaptability. Access to psychosocial support, peer mentoring programs, and educational accommodations can enhance coping mechanisms and promote a more positive outlook. These interventions can significantly bolster HRQoL by fostering a sense of inclusion and empowerment [49].

The transition from pediatric to adult care poses another critical challenge. Adolescents with PIDD often face uncertainty regarding their future health, education, and employment prospects. Ensuring a structured transition process, including counseling and life-skills training, is vital to maintaining continuity of care and sustaining HRQoL into adulthood [50].

The availability and accessibility of specialized healthcare services significantly influence the HRQoL of children with PIDD. In regions with limited access to immunologists or appropriate therapies, children may face prolonged illness and complications. Disparities in healthcare infrastructure underscore the need for global health initiatives aimed at equitable care provision [51].

Cultural perceptions of chronic illness can also affect how children with PIDD and their families perceive and manage the condition. In some societies, stigma surrounding genetic disorders may lead to social exclusion and reluctance to seek medical care, thereby worsening HRQoL outcomes. Culturally sensitive interventions are necessary to address these barriers effectively [52].

Technological advances such as telemedicine have improved access to care for many children with PIDD, especially in remote or underserved areas. Regular virtual consultations can enhance disease monitoring and provide timely interventions, reducing the need for hospital visits and supporting better HRQoL outcomes [53].

Patient and family education play a pivotal role in disease management and HRQoL. Providing accurate information about PIDD, treatment options, and self-care strategies empowers families to take an active role in care decisions. This knowledge reduces uncertainty and anxiety, contributing to improved emotional well-being [54].

Support groups and patient advocacy organizations offer vital resources for children with PIDD and their families. These platforms provide emotional support, shared experiences, and advocacy for better healthcare policies. Participation in such communities can alleviate feelings of isolation and foster a sense of belonging, enhancing HRQoL [55].

Psychological counseling and behavioral therapy are effective in addressing the emotional challenges faced by children with PIDD. Cognitive-behavioral interventions have been shown to reduce symptoms of anxiety and depression, improve coping strategies, and ultimately elevate HRQoL scores in this population [56].

School-based interventions, including individualized education plans (IEPs) and teacher awareness programs, can accommodate the unique needs of children with PIDD. These efforts help ensure educational continuity and social integration, both of which are crucial for maintaining HRQoL [57].

Research into gene therapy and other emerging treatments offers hope for curative approaches to PIDD. Clinical trials have demonstrated promising results in correcting underlying genetic defects, potentially transforming the disease trajectory and significantly improving HRQoL in the future [58].

Policymakers and healthcare providers must collaborate to develop comprehensive care models that integrate medical, psychological, educational, and social support services for children with PIDD. Such holistic care frameworks are essential to optimizing HRQoL and enabling these children to lead fulfilling lives despite their chronic condition [59].

REFERENCES

1. Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2022 Primary Immunodeficiency Diseases Committee Report. J Clin Immunol. 2022;42(7):1473-1507.

2. Bonilla FA, Barlan I, Chapel H, et al. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. J Allergy Clin Immunol Pract. 2016;4(1):38-59.
3. Sullivan KE. Evaluation of the child with recurrent infections. In: UpToDate. Available from: https://www.uptodate.com

4. Modell V, Quinn J, Ginsberg G, et al. Modeling strategy to identify patients with primary immunodeficiency utilizing risk management and outcome measurement. Immunol Res. 2017;65(3):713-720.
5. Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2019 Update. J Clin Immunol. 2020;40(1):24-64.
6. Conley ME, Dobbs AK, Quintana AM, et al. Genetic analysis of patients with defects in early B-cell development. Immunol Rev. 2005;203:216-234.
7. Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112(2):277-286.
8. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol. 2004;22:625-655.
9. Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729-738.
10. Holland SM. Chronic granulomatous disease. Hematol Oncol Clin North Am. 2013;27(1):89-99.
11. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev. 1991;4(3):359-395.
12. Goyal R, Bulua AC, Nikolov NP, et al. Rheumatologic and autoimmune manifestations of primary immunodeficiency disorders. Curr Opin Rheumatol. 2009;21(1):78-84.
13. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am. 2008;28(4):779-802.
14. Pai SY, Cowan MJ. Stem cell transplantation for primary immunodeficiency diseases: the North American experience. Curr Opin Allergy Clin Immunol. 2014;14(6):521-526.
15. Mamcarz E, Zhou S, Lockey T, et al. Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1. N Engl J Med. 2019;380(16):1525-1534.
16. Shearer WT, Fleisher TA, Buckley RH, et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol. 2014;133(4):961-966.
17. Waltenburg JL, Mehta A, Waltenburg A. Managing the psychosocial burden of primary immunodeficiency. Pediatr Allergy Immunol Pulmonol. 2014;27(4):183-188.
18. Modell F, Puente D, Modell V. From genotype to phenotype: Further studies measuring the impact of early diagnosis and intervention in primary immunodeficiency diseases. Immunol Res. 2007;38(1-3):103-111.
19. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S182-S194.
20. Bousfiha A, Jeddane L, Picard C, et al. The 2020 IUIS Phenotypical Classification for Primary Immunodeficiencies. J Clin Immunol. 2020;40(1):66-81.
21. Picard C, Al-Herz W, Bousfiha A, et al. Primary immunodeficiency diseases: an update on the classification from the IUIS Expert Committee. J Clin Immunol. 2020;40(1):66-81.
22. Bonilla FA, Barlan I, Chapel H, et al. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. J Allergy Clin Immunol Pract. 2016;4(1):38-59.
23. Ochs HD, Oukka M, Torgerson TR. T H17 cells and regulatory T cells in primary immunodeficiency disorders. Curr Opin Allergy Clin Immunol. 2009;9(6):547-552.
24. Shearer WT, Fleisher TA, Buckley RH, et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol. 2014;133(4):961-966.
25. Bousfiha A, Jeddane L, Picard C, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40(1):24-64.

26. Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729-738.
27. Meyts I, Bucciol G, Quinti I, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Allergy Clin Immunol. 2021;147(2):520-531.
28. Marciano BE, Rosenzweig SD, Holland SM. Primary immunodeficiencies associated with susceptibility to mycobacterial infections. Curr Opin Rheumatol. 2008;20(4):429-437.
29. Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112(2):277-286.
30. Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome: report from the 2009 NIH International Workshop. Blood. 2010;116(14):e35-e40.
31. Mian AI, Rosen FS, Geha RS, et al. Update on primary immunodeficiencies: A report from the AAAAI Primary Immunodeficiency Committee. J Allergy Clin Immunol. 2008;122(4):897-909.
32. Zhu Q, Zhang M, Blaese RM, et al. The Wiskott-Aldrich syndrome: diagnostic and molecular studies. Immunol Res. 2009;44(1-3):18-32.
33. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S182-S194.
34. Verbsky JW, Routes JM. Primary immunodeficiency disorders in children: an overview. Pediatr Clin North Am. 2005;52(5):1559-1579.
35. Fischer A, Provot J, Jais JP, et al. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. J Allergy Clin Immunol. 2017;140(5):1388-1393.e8.
36. Sullivan KE. Diagnosis and management of immunodeficiency. J Allergy Clin Immunol. 2020;145(2):435-446.
37. Modell V, Orange JS, Quinn J, et al. Global report on primary immunodeficiencies: 2018 update from the Jeffrey Modell Foundation. Immunol Res. 2018;66(3):367-380.
38. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol. 2004;22:625-655.
39. Jeffrey Modell Foundation. 10 Warning Signs of Primary Immunodeficiency. Accessed March 2025. https://www.info4pi.org
40. Al-Herz W, Bousfiha A, Casanova JL, et al. Primary immunodeficiency diseases: an update on the classification from the IUIS Expert Committee for Primary Immunodeficiency. Front Immunol. 2014;5:162.
41. Bousfiha A, Jeddane L, Picard C, et al. Human inborn errors of immunity: 2019 update of the IUIS Phenotypical Classification. J Clin Immunol. 2020;40(1):66-81.
42. Rider NL, Miao D, Shapiro R. Health-Related Quality of Life in Primary Immunodeficiency Diseases. Curr Allergy Asthma Rep. 2019;19(11):52.
43. Modell V, Quinn J, Orange J. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front Immunol. 2021;12:688622.
44. Bonilla FA, Barlan I, Chapel H, et al. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. J Allergy Clin Immunol Pract. 2016;4(1):38-59.
45. Cohen B, Vadasz Z, Kfir-Erenfeld S, et al. Health-related quality of life and psychological status in parents of children with primary immunodeficiency. Allergy Asthma Proc. 2019;40(1):55-61.
46. Titman P, Pink E, Skucek E, et al. Quality of life in children with primary antibody deficiency. J Clin Immunol. 2014;34(4):844-852.

47. Gardulf A, Nicolay U, Asensio O, et al. Health-related quality of life in adults with primary antibody deficiencies treated with subcutaneous IgG. Clin Immunol. 2004;110(2):238-246.
48. Patel NC, Hertweck SP, Byrne BJ. The impact of primary immunodeficiency diseases on health-related quality of life in children and adolescents. Curr Opin Pediatr. 2020;32(6):849-855.
49. van Montfrans JM, Hoepelman IM, van Gageldonk PG, et al. Long-term follow-up of children with antibody deficiency. Pediatrics. 2005;115(6):1407-1414.
50. Seidel MG, Kindle G, Gathmann B, et al. The European Society for Immunodeficiencies (ESID) Registry Working Party: improving the quality of PID research and care. Clin Exp Immunol. 2014;175(3):349-357.
51. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27(5):497-502.
52. Shillitoe R. Chronic illness and the family: a social psychological analysis. Soc Sci Med. 1988;27(2):101-112.
53. Aljaberi MA, Alsmadi S, Al-Qudah M, et al. Role of telemedicine in managing primary immunodeficiency diseases during COVID-19 pandemic. J Telemed Telecare. 2021;27(5):261-266.
54. Route TL, Sosa JM, Abraham RS. Comprehensive care for primary immunodeficiency: A model for patient and family education. Immunol Allergy Clin North Am. 2020;40(2):425-438.
55. McCusker C, Warrington R. Primary immunodeficiency. Allergy Asthma Clin Immunol. 2011;7(Suppl 1):S11.
56. Perkinson M, Oliver BJ, Frayman KB, et al. Psychological support in chronic pediatric illness: effectiveness and delivery models. Child Adolesc Psychiatr Clin N Am. 2020;29(2):343-360.
57. Panicker S, Sachdeva S. Academic and social inclusion of children with chronic illnesses: A school-based perspective. Indian J Pediatr. 2021;88(7):663-669.
58. Mamcarz E, Zhou S, Lockey T, et al. Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1. N Engl J Med. 2019;380(16):1525-1534.
59. Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the AAAAI. J Allergy Clin Immunol. 2012;130(3 Suppl):S1-S24.